A PHASE IIB STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF AZD8965 IN PARTICIPANTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) (ARGINAUT)

Registry ID

D6960C00005

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2026-07-16

Last update

2026-04-10

Conditions

• PULMONARY FIBROSIS

Related clinical trials

• A MULTINATIONAL, LONG-TERM, OPEN-LABEL EXTENSION STUDY OF SUBJECTS WHO HAVE PARTICIPATED IN AVALYN PHARMA STUDIES OF INHALED ANTIFIBROTIC AGENTS (AP-LTE-008 [SAIL])
• A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF ENV-101 IN PATIENTS WITH LUNG FIBROSIS (WHISTLE-PF TRIAL)
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2B STUDY EVALUATING THE SAFETY AND EFFICACY OF PIRFENIDONE SOLUTION FOR INHALATION (AP01) IN SUBJECTS WITH PROGRESSIVE PULMONARY FIBROSIS (PPF)
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF INHALED TREPROSTINIL IN SUBJECTS WITH PROGRESSIVE PULMONARY FIBROSIS (TETON-PPF)
• AN OPEN-LABEL EXTENSION TRIAL OF THE LONG-TERM SAFETY AND EFFICACY OF BI 1015550 TAKEN ORALLY IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND PROGRESSIVE PULMONARY FIBROSIS (PPF) (FIBRONEER¿-ON)
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BMS-986278 IN PARTICIPANTS WITH PROGRESSIVE PULMONARY FIBROSIS

View on source registry